A Meta-Analysis of the Treatment of Diabetic Nephropathy using Astragalus Injection combined with Captopril

Abstract

To observe the effectiveness and safety of using astragalus injection combined with captopril for diabetic nephropathy. The method is using computer database searches and manual retrieval of relevant journals. Astragalus injection combined with captopril was the test drug group. The data was analyzed using Review Manager 5.1 according to the evaluation criteria of RCT recommended by Cochrane 4.2.2. 11RCT and total 641 cases of early and clinical diabetic nephropathy were included. Astragalus injection combined with captopril was more excellent than the control group in the lower of 24hUAER [MD=-21.09, (-37.21,-4.96), P<0.01], 24h urinary protein [MD =- 0.38, (- 47, -0.28), P <0.01], the efficient [RR=1.29, (1.06,1.57), P=0.01], BUN [MD=-0.36, (-0.62,-0.11), P=0.004], SCr [MD=-4.13, (-7.94,-0.33), P=0.03], FPG [MD=-0.96, (-1.67,-0.24), P=0.009], TC [MD=-1.42, (-1.66,-1.18), P<0.01], and TG [MD=-0.45, (-0.59,-0.32), P<0.01]. There was no significance in 2h PG [MD=-0.07, (-0.65,0.51), P=0.81], and blood pressure (2 =0.15, P=0.69).. Astragalus injection combined with captopril was effect and safe in the lower of 24hUAER and the efficient for the patients with diabetic nephropathy. It also needs more randomized controlled trials for high-quality evaluation.